BRIDGEWATER, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Clinical Genomics, a leading provider of cancer diagnostic solutions including liquid biopsy tests, today announced the appointment of Roy Davis as Senior Advisor and Board Member. Mr. Davis joins the organization with over 30 years of experience in leadership and business development, strategic planning and creating joint ventures across the US, Europe and Japan.
“We are pleased to welcome Roy as our newest Board Member. He brings a deep understanding of healthcare and commercial expertise to our team. We are very fortunate to have him by our side as we continue to carry out our mission,” said Lawrence LaPointe, Ph.D., CEO of Clinical Genomics. “Roy will be an asset to our Board of Directors, and provide valuable counsel to the organization.”
Mr. Davis spent twenty-seven years with Johnson & Johnson including as Group President before serving as Company Group Chairman and Worldwide Franchise Chairman for the Company and then President of J & J Development Corporation. Mr. Davis also held Managing Director and General Manger roles for Ortho Diagnostics in Europe, Japan and the Americas. Mr. Davis was the founding President of Veridex (a Johnson & Johnson Company), one of the first organizations to introduce breakthrough technology in the field of circulating tumor cells. More recently, Mr. Davis served as Innovations Advisory Board Member for Cleveland Clinic. Mr. Davis is currently a Senior Advisor for Huron Global Management Consulting and its Innosight subsidiary.
Mr. Davis received a Bachelor of Science from the University of Albany, SUNY, and a Master of Science from Rensselaer Polytechnic Institute.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™ and InSure® ONE™, fecal immunochemical tests for screening in healthy adults, to COLVERA™, a proprietary liquid biopsy test identifying circulating tumor DNA in patient’s post-treatment for early detection of recurrence and residual disease. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.
Source: Clinical Genomics